Differentiating T-Cell Engager Use Vs Normal Therapy in A number of Myeloma

Trials evaluating T-cell engagers in sufferers with a number of myeloma could successfully mitigate antagonistic results (AEs) associated to infections by observing sufferers following a hard and fast period of therapy, in keeping with Shebli Atrash, MD.

In an interview with CancerCommunity®, Atrash, medical oncologist at Levine Cancer Institute and medical affiliate professor of Medicine at Wake Forest University, outlined issues for T-cell engager use in sufferers with a number of myeloma following a presentation he gave on the 2025 Immune Cell Effector Therapy (ICE-T) Conference.

He started by suggesting that T-cell therapies have been transformative for the a number of myeloma panorama when in comparison with different requirements of care, producing deeper and extra sturdy responses, in addition to fewer AEs. The major drawback, he said, is the incidence of infections.

Noting that infections are generally seen with these brokers, he outlined the AEs most frequently noticed with their use, together with pores and skin and nail adjustments, dysgeusia, and weight reduction. He concluded by explaining that researchers are exploring mounted dosing for T-cell engagers, with commentary occurring following therapy, to assist mitigate extended AEs related to infections.

Transcript:

T-cell engagers have modified the a number of myeloma panorama. They have produced deep responses that we’ve got not seen with different brokers. The benefits of T-cell engagers [include fewer] general [adverse] results, a [more] handy administration––we’re speaking about one drug, [fewer] steroids––and extra sturdy responses. The drawback of bispecifics is infections.

Infections have been frequent for BCMA-targeting bispecifics. For GPRC5D, [common] antagonistic occasions [include] pores and skin rash, dysgeusia, and weight reduction, in addition to nail adjustments. Those have been the determinants of therapy. Regarding an infection, we’ve got profitable concepts which have been circulating concerning the mounted period of therapy. This means you deal with with bispecific antibodies for, say, a yr or 2, and then you definitely cease and [observe patients]. Those concepts are nonetheless untimely, however [many] trials are going that method.

Reference

Atrash S. Emerging T-cell engagers & novel immunotargets in a number of myeloma. Presented on the 2025 National Immune Cell Effector Therapy (ICE-T) Conference; July 26, 2025; Orlando, FL.